BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
231.27
-0.96 (-0.41%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close232.23
Open232.86
Bid230.04 x 1200
Ask231.27 x 900
Day's Range231.09 - 233.85
52 Week Range216.12 - 388.67
Volume1,315,791
Avg. Volume1,749,307
Market Cap44.842B
Beta (3Y Monthly)1.51
PE Ratio (TTM)9.99
EPS (TTM)23.14
Earnings DateJul 23, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est253.00
Trade prices are not sourced from all markets
  • Federal judge blocks Trump Administration's proposal to include wholesale drug prices in TV ads
    Yahoo Finance Video11 days ago

    Federal judge blocks Trump Administration's proposal to include wholesale drug prices in TV ads

    A federal judge dealing a blow to the Trump Administration by striking down a new rule that would have forced pharma companies to include the wholesale prices of their drugs in TV ads. Yahoo Finance's Seana Smith and Alexis Keenan discuss.

  • Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?
    Zacks22 hours ago

    Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?

    While sales of Biogen's (BIIB) MS franchise are expected to decline in the second quarter of 2019, Spinraza U.S. sales may improve.

  • The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On
    Motley Fool3 days ago

    The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On

    Gene therapy developers might steal all of the headlines, but manufacturing is likely to be the more lucrative investing opportunity -- for both companies and investors.

  • Eisai boosts focus on Alzheimer's with new research facility, funding
    American City Business Journals4 days ago

    Eisai boosts focus on Alzheimer's with new research facility, funding

    Japanese drugmaker Eisai is investing $120 million over three years in an Alzheimer's research center — a 20 percent increase over the funding Eisai originally had allocated for the facility.

  • Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth
    Zacks4 days ago

    Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth

    Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Amgen & Novartis' Alzheimer Studies End in Another Failure
    Zacks8 days ago

    Amgen & Novartis' Alzheimer Studies End in Another Failure

    Amgen (AMGN) and Novartis (NVS) discontinue two Alzheimer's disease studies. Alzheimer's has always been a highly challenging area with many studies failing.

  • 2 Falling Pharma Stocks Whose Star May Rise in 2019
    TipRanks9 days ago

    2 Falling Pharma Stocks Whose Star May Rise in 2019

    Here are two pharmaceutical companies that are presently being downgraded by analysts but that are expected to gain strength as the year progresses. It’s an inversion of the axiom, “Past performance is not guarantee of future results.” The risk of investing in them may be large but so are the potential rewards for farsighted investors. AbbVieAbbVie (ABBV) has been experiencing a drop in its shares for the last several months. The major reason for its decline is its biologic immunology drug Humira accounting for the biggest part of its revenue.Humira sales have been weaker lately. Rated as one of the top-selling drugs in 2018, Humira started losing a competition with cheaper medicines in 2019. In the first quarter of this year, it brought in revenue of $4.45 billion, which is 5.6% less than the company’s last year revenue.AbbVie faced other setbacks. Its cancer drug Rova-T failed to become a great commercial success. AbbVie’s testing of Venclexta, a multiple myeloma drug, was not successful either and negatively affected its stock. Over the past 12 months, AbbVie’s shares dipped 14%. Its net earnings decreased to $1.65 per share in the first quarter of 2019, from $1.74 per share a year earlier.On June 25, AbbVie announced a definitive agreement to acquire Allergan (AGN) in a cash and stock transaction for a total consideration of $63 billion. The news worked to its financial disadvantage. As soon as AbbVie’s intentions became known, its stock sank 16%, because investors estimated its plans as a mistake. When investors recovered from the news, AbbVie’s stock went up - but only slightly so. As a result, for the last six months, analysts have strongly been advising to put any investment in AbbVie on hold. As of writing, the average price given by analysts to the company’s shares is $79.33, with only 10.95% upside. Yet there are positive signs that AbbVie can soon stop its downward progression. It has recently signed lucrative deals with Mylan NV and Amgen Inc (AMGN). It is also working on a new cancer drug called Imbruvica. The drug may help move abnormal B cells out of their nourishing environment in the lymph nodes, bone marrow, and other organs.In June, Imbruvica was ranked as the fifth drug thought to become a blockbuster in the near future. According to EvaluatePharma, AbbVie’s new drug may bring it $9.5 billion in sales in 2024. The company’s two other drugs – Orilissa and Skyrizi – are also expected to sell well and thus enlarge its profits. After the projection made by EvaluatePharma, Goldman Sachs analyst Terence Flynn increased his price target to $84. He thinks that the sales from AbbVie’s cancer drugs and new immunology drugs will generate enough revenue to balance out the losses brought by Humira. Other analysts hope for the company’s strength, too. As AbbVie approaches its Q2 earnings release, analysts expect that it will report $2.21 per share, which would represent year-over-year growth of 10.5%. The blogger Wolf Report agrees: “ I'm bullish on AbbVie. It remains one of my largest pharma stocks, and I'm willing to add more, should the opportunity present itself. And I believe that it now has, and may even improve going forward.”Analyst Ratings & Price Targets on AbbVie BiogenBiogen (BIIB) had a rough start of the year. Within the first six months of 2019, the company tumbled by 22.3%, erasing 17 billion in valuation. There are several reasons for Biogen’s unsightly decline. One is the failure of the Alzheimer’s project aducanumab. At two late-stage trials it became clear that the anti-amyloid MAb, which Biogen believed would clear amyloid lesions, could not prevent the disease.Biogen’s shares also dropped because of the competition with Novartis (NVS). Its drug Spinraza that cures pediatric spinal muscular atrophy and generates the bulk of its profits can be upstaged by Novartis’s recently approved medicine Zolgensma. The Institute for Clinical and Economic Review (ICER) said in January that Zolgensma, which also treats spinal muscular atrophy in small children, could be more cost-effective than Biogen’s drug with a one-time price of $2 million. Biogen’s multiple-sclerosis franchise also failed to live up to its promise, undermined by a competition with such companies as Roches and Novartis. A preferable alternative to Biogen’s main MS medicines, Tysarabi and Tecfidera, Roches’ drug Ocrevus has been diminishing Biogen’s profits since the third quarter of 2017. This year, the competition between the MS medicine producers intensified, when Novartis introduced Mayzent that costs about $88,500 a year. This is about 7% less than Biogen’s Tysarabi and Tecfidera.But Biogen still has several ongoing medical trials to its credit. It is presently developing its next MS medicine Vumerity, whose approval might happen later this year. Investors may also follow Biogen’s earlier-stage pipeline for inherited disease of the eye, pain management, and cardiovascular disease. Biogen might also make several acquisitions in 2019. There are rumors that its recent purchase of Nightstar Therapeutics, a gene therapy company, will be followed by other acquisitions. Analysts suggest that such companies as Neurocrine Bioscience (NBIX), Sage Therapeutics (SAGE), and Ionis Pharmaceuticals (IONS) would enhance Biogen’s holdings. But even if no additional purchase is made, Nightstar Therapeutics can become for Biogen a useful springboard for building an eye disease franchise that will push its profit up in the coming several years. True, some analysts advise not to invest in Biogen for the time being, but there are others who are bullish on its stock. H.C. Wainwright analyst Andrew Fein maintains a Buy rating on Biogen, with a price target of $300. Analyst Ratings & Price Targets on Biogen Inc

  • Will Patent Woes Boost Pharma Stock Megamergers Further?
    Zacks10 days ago

    Will Patent Woes Boost Pharma Stock Megamergers Further?

    With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.

  • Top Analyst Reports for Boeing, 3M & U.S. Bancorp
    Zacks11 days ago

    Top Analyst Reports for Boeing, 3M & U.S. Bancorp

    Top Analyst Reports for Boeing, 3M & U.S. Bancorp

  • Skyhawk Therapeutics adds Merck to nest of drug partners
    American City Business Journals12 days ago

    Skyhawk Therapeutics adds Merck to nest of drug partners

    Roughly 18 months after launching with $8 million in seed financing, the startup has developed a long list of partners, primarily those looking to tackle neurological diseases.

  • Why Biogen Stock Has Plummeted in 2019
    Motley Fool12 days ago

    Why Biogen Stock Has Plummeted in 2019

    Biogen's swing and miss in Alzheimer's disease has weighed on its shares this year.

  • Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
    Zacks12 days ago

    Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?

    Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Barrons.com15 days ago

    Biogen Revenue Has the Potential to Meet Wall Street Expectations, Analyst Says

    Biogen stock is down 21% since the start of the year, but Citi Research sees some light at the end of the tunnel.

  • Is Biogen Inc.'s (NASDAQ:BIIB) ROE Of 34% Impressive?
    Simply Wall St.15 days ago

    Is Biogen Inc.'s (NASDAQ:BIIB) ROE Of 34% Impressive?

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

  • American City Business Journals17 days ago

    Here are the Mass. firms with the highest — and lowest — profits per employee

    We compared 96 Massachusetts-based public companies on a metric proposed in 2007 by McKinsey & Co. as an alternative to measuring companies solely by return on investment capital.

  • Why These 4 Biotech Leaders Could Rebound On Strong Earnings
    Investor's Business Daily17 days ago

    Why These 4 Biotech Leaders Could Rebound On Strong Earnings

    Large biotech companies Gilead Sciences and Vertex Pharmaceuticals are poised to beat Wall Street's second-quarter revenue expectations, according to investment bank RBC Capital Markets.

  • GuruFocus.com17 days ago

    2 Health Care Companies to Consider for the 2nd Half of the Year

    Stocks are trading below Peter Lynch value

  • Atara Reports Initial Data for Multiple Sclerosis Candidate
    Zacks19 days ago

    Atara Reports Initial Data for Multiple Sclerosis Candidate

    Atara (ATRA) announces initial ATA188 phase I safety results for patients with progressive MS.

  • Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
    PR Newswire19 days ago

    Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients

    - New results from the NURTURE study demonstrate that pre-symptomatic infants treated with SPINRAZA are achieving motor milestones that are unprecedented in the natural history of the disease, including ...

  • 3 Top Biotech Stocks to Buy Right Now
    Motley Fool20 days ago

    3 Top Biotech Stocks to Buy Right Now

    These three biotech stocks should be outstanding long-term growth vehicles.

  • GlobeNewswire21 days ago

    Biogen announces European label update for SPINRAZA (nusinersen) which includes longer-term data across a broad range of ages and types of Spinal Muscular Atrophy

    Biogen (BIIB) today announced an update to the European label for nusinersen, incorporating longer-term data from four studies (NURTURE, EMBRACE, SHINE and CS3A). No new safety concerns were identified.

  • Options Bulls Continue to Blitz Embattled Biogen Stock
    Schaeffer's Investment Research22 days ago

    Options Bulls Continue to Blitz Embattled Biogen Stock

    The biotech was downgraded at Piper Jaffray earlier

  • TheStreet.com22 days ago

    Biogen Drops After Piper Jaffray Downgrade, Price Target Cut

    shares were falling in trading Friday after analysts at Piper Jaffray downgraded the stock to neutral from overweight on concerns about competitive pressures for the suite of the company's multiple sclerosis treatments.

  • Barrons.com22 days ago

    Biogen Stock Is Slipping Because a Multiple Sclerosis Drug Has Fierce Competition

    Biogen stock was slipping as one analyst warned that the company’s drug for multiple sclerosis could be losing ground to new competitors.